Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

tstanding.

Interest expense, net of capitalized interest and taxes was $10,331

and $33,948 for the 2007 fourth quarter and full year, respectively,

compared with $8,168 and $30,009 for the 2006 fourth quarter and full

year, respectively.

(3) Charges related to activities associated with the Company's

productivity initiatives and the 2006 income tax adjustment are

considered certain significant items and have been excluded from the

results of operations -- as adjusted for the 2007 and 2006 fourth

quarter and full year as follows:

Productivity Initiatives

(UNAUDITED)

Three Months Ended Full Year Ended

(In thousands, except 12/31/07 12/31/06 12/31/07 12/31/06

per share amounts)

Cost of Goods Sold $62,000 $42,700 $244,300 $129,200

Selling, General and

Administrative Expenses 1,900 23,200 28,800 78,000

Research and Development

Expenses - (2,100) 300 11,400

Total Productivity

Initiatives Charges $63,900 $63,800 $273,400 $218,600

Productivity Initiatives

Charges, After-tax $41,900 $48,100 $194,400 $154,500

Decrease in Diluted

Earnings per Share $0.03 $0.03 $0.14 $0.11

Income Tax Adjustment

The 2006 full year results include an income tax adjustment of $70.4

million ($0.05 per share-diluted) related to the reduction of certain

deferred tax asset valuation allowances.

Wyeth calculates net income before certain significant items by excluding the after-tax effect of items considered by management to be unusual from the net income reported under gene
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has ... Africa Biomedical Sensors Market - Growth, Trends & Forecasts ... The Middle East & Africa ... 2018 at a CAGR of 3.26% over the period ... sensors that are adaptable to the genetic formulation of ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... high priority in the drug development approval process. Thus, innovator companies must understand ... Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... The state will give $250,000 in tax credits to C3 ... an 18,000-square-foot facility in Appleton's Northeast Business Park. , ,According ... create 28 jobs in the area. The credits are part ... aside $5 million in tax credits for each of eight ...
... up with UW-Eau Claire, UW-Stout and several other tech ... in the state. , ,Nanotechnology deals with particles one ... physical properties of matter begin to give way to ... understand. The potential of arranging nanoparticles, which scientists long ...
... the University of Wisconsin-Madison are taking another look at some ... That's what scientists call the way sounds change as you ... example, a jackhammer or a siren will sound higher pitched ... ,But there's an inverse Doppler effect, too, predicted ...
Cached Biology Technology:Chippewa Valley Technical College helps pioneer nanotech program, incubator 2Chippewa Valley Technical College helps pioneer nanotech program, incubator 3Chippewa Valley Technical College helps pioneer nanotech program, incubator 4
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... when the Food and Drug Administration is reconsidering the ... study offers further evidence to support a University of ... treatment may be in order. Richard ... Houston College of Pharmacy (UHCOP), has been investigating whether ...
... Ill. -- Most people know that too much sodium from ... that people trying to lower their blood pressure should also ... to sodium. Researchers found that the ratio of sodium-to-potassium ... disease than sodium or potassium alone. "There isn,t ...
... the first clinical evidence that gene therapy reduces symptoms ... this promising treatment which has endured a sometimes turbulent ... Human Gene Therapy the findings stem from ... conducted in Germany and led by an investigator at ...
Cached Biology News:New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4Cutting salt isn't the only way to reduce blood pressure 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: